News - Astellas Pharma, Asia-Pacific

Filter

Popular Filters

1 to 25 of 29 results

Astellas gains Japanese clearance for diabetes drug Suglat

Astellas gains Japanese clearance for diabetes drug Suglat

20-01-2014

Japanese drug major Astellas Pharma has obtained the marketing approval of selective SGLT2 inhibitor…

Asia-PacificAstellas PharmaDiabetesipragliflozinKotobuki PharmaceuticalMerck & CoPharmaceuticalRegulationSuglat

Astellas and UMN update on Ph III trials of flu vaccine ASP7374; debuts Irribow OD in Japan

Astellas and UMN update on Ph III trials of flu vaccine ASP7374; debuts Irribow OD in Japan

15-01-2014

Japanese drug major Astellas Pharma and partner UMN Pharma have announced promising summary results for…

Asia-PacificASP7374Astellas PharmaGastro-intestinalsIrribowMarkets & MarketingPharmaceuticalResearchUMN PharmaVaccines

Medivation and Astellas reveal positive Phase III results for prostate cancer drug

Medivation and Astellas reveal positive Phase III results for prostate cancer drug

23-10-2013

Medivation and Japanese drug major Astellas Pharma have announced positive results from the Phase III…

Asia-PacificAstellas PharmaenzalutamideMedivationOncologyPharmaceuticalResearchXtandi

Astellas’ antifungal study reports positive results

30-09-2013

Astellas Pharma has announced positive topline data from the Phase III invasive aspergillosis study (SECURE)…

Asia-PacificAstellas PharmaBasilea PharmaceuticaDermatologicalsisavuconazolePharmaceuticalResearch

Prostate cancer market set to grow 50% by 2021: report

06-09-2013

The increasing number of sufferers and the uptake of new drugs will see the prostate cancer market grow…

Asia-PacificAstellas PharmaEuropeJohnson & JohnsonMarkets & MarketingNorth AmericaOncologyPharmaceuticalXtandiZytiga

Merck & Co to co-promote diabetes agent ipragliflozin in Japan

02-09-2013

Japanese drug major Astellas Pharma (TYO: 4503) has entered into a co-promotion agreement in Japan with…

Asia-PacificAstellas PharmaDiabetesipragliflozinKotobuki PharmaceuticalLicensingMarkets & MarketingMerck & CoPharmaceutical

Astellas gains marketing approval for Irribow

16-08-2013

Japanese drug major Astellas Pharma (TYO: 4503) has gained marketing approval in Japan for Irribow (ramosetron…

Asia-PacificAstellas PharmaGastro-intestinalsIrribowMarkets & MarketingPharmaceutical

AstraZeneca to fork out $815 million for rights to anemia drug candidate

31-07-2013

In yet another move to boost its R&D pipeline, Anglo-Swedish drug major AstraZeneca (LSE: AZN) has entered…

Asia-PacificASP1517Astellas PharmaAstraZenecaBiotechnologyFG-4592FibroGenLicensingNephrology and HepatologyNorth AmericaPharmaceuticalResearch

Additional indications in Japan for Roche's Avastin and Astellas' Prograf

17-06-2013

Swiss drug major Roche (ROG: SIX) says that the Japanese Ministry of Health, Labor and Welfare (MHLW)…

Asia-PacificAstellas PharmaAvastinBiotechnologyImmunologicalsOncologyPharmaceuticalPrografRegulationRoche

Amgen and Astellas link up on drugs for unmet medical needs in Japan

29-05-2013

World leading independent biotech firm Amgen (Nasdaq: AMGN) has joined forces with Japanese drug major…

AmgenAnti-Arthritics/RheumaticsAsia-PacificAstellas PharmaBiotechnologyCardio-vascularOncologyPharmaceuticalResearch

Astellas and Medivation file for approval of enzalutamide in Japan

24-05-2013

Japanese drug major Astellas Pharma (TYO: 4503) has submitted an application for marketing approval of…

Asia-PacificAstellas PharmaenzalutamideMedivationOncologyPharmaceuticalRegulationXtandi

MHLW joins Japan's first P-PP to facilitate R&D of new health technologies for the developing world

08-04-2013

The Japanese Ministry of Health, Labor and Welfare (MHLW) has said it supports the research and development…

Asia-PacificAstellas PharmaDaiichi SankyoEisaiFinancialHealthcarePharmaceuticalResearchShionogiTakeda PharmaceuticalsTropical diseases

Zeria and Astellas' Acofide approved in Japan for functional dyspepsia

27-03-2013

Japan's Ministry of Health, Labor and Welfare (MHLW) has approved the marketing of Acofide (acotiamide…

AcofideAsia-PacificAstellas PharmaGastro-intestinalsPharmaceuticalRegulationZeria Pharmaceuticals

Astellas files for Japanese approval of ipragliflozin for types 2 diabetes

14-03-2013

Japanese drug major Astellas Pharma (TYO: 4503) has submitted a market authorization application for…

Asia-PacificAstellas PharmaDiabetesipragliflozinPharmaceuticalRegulation

Kyowa Hakko and Astellas get new indication for Pasetocin and Sawacillin; latter applies for new Dormicum use

21-02-2013

Japanese drug major Kyowa Hakko Kirin (TYO: 4151) and Astellas Pharma (TYO: 4503) have jointly announced…

Asia-PacificAstellas PharmaDormicumGastro-intestinalsKyowa Hakko KirinNeurologicalPasetocinPharmaceuticalRegulationSawacillin

Takeda's leadership as Japan's largest drugmaker set to decline, says DR

29-10-2012

Based on full-year 2011 sales, Japan's Takeda Pharmaceutical (TYO: 4502) maintained its position as the…

Asia-PacificAstellas PharmaFinancialPharmaceuticalResearchTakeda Pharmaceuticals

Astellas collaborates with AIST for neglected tropical diseases

23-10-2012

Japanese drug major Astellas Pharma (TYO: 4503) has signed a collaborative drug discovery research agreement…

Asia-PacificAstellas PharmaPharmaceuticalResearchTropical diseases

Astellas launches RLS drug Regnite in Japan

10-07-2012

Japanese drug major Astellas Pharma (TOY: 4503) says that Regnite (gabapentin enacarbil) extended-release…

Asia-PacificAstellas PharmaMarkets & MarketingNeurologicalPharmaceuticalRegniteXenoPort

Eisai and Toyama's iguratimod, and Astellas' Gonax OKed in Japan

03-07-2012

Japanese drug major Eisai (TYO: 4523) and Toyama Chemical have received approval from Japan's Ministry…

Anti-Arthritics/RheumaticsAsia-PacificAstellas PharmaCareramdegarelixEisaiFerring PharmaceuticalsGonaxiguratimodKolbetOncologyPharmaceuticalRegulationToyama

Astellas debuts Kiklin capsules, for hyperphosphatemia, in Japan

26-06-2012

Japanese drug major Astellas Pharma (TYO: 4503) yesterday launched Kiklin capsules 250mg (bixalomar)…

Asia-PacificAstellas PharmaKiklinMarkets & MarketingNephrology and HepatologyPharmaceuticalSanwa Kagaku

Optimer Pharma could earn $90 million from new Astellas deal

30-03-2012

US firm Optimer Pharmaceuticals (Nasdaq: OPTR) has entered into a second deal with Japanese drug major…

Antibiotics and Infectious diseasesAsia-PacificAstellas PharmaDificidfidaxomicinLicensingOptimer PharmaceuticalsPharmaceutical

Additional indications in Japan for Diagnogreen and Sawacillin

22-02-2012

Japanese drug major Daiichi Sankyo (TYO: 4568) says it has received approval in Japan for a supplemental…

Antibiotics and Infectious diseasesAsia-PacificAstellas PharmaDaiichi SankyoPharmaceuticalRegulationSawacillin

Astellas and Sanwa to co-promote kidney disease drugs in Japan

21-02-2012

Japanese drug major Astellas Pharma (TYO: 4503) yesterday revealed that it has linked up with fellow…

ArgamateAsia-PacificAstellas PharmabixalomerMarkets & MarketingNephrology and HepatologyPharmaceuticalSanwa Kagaku

1 to 25 of 29 results

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top